10-Q · May 14, 2026
Autolus Therapeutics reported significant growth in Q1 2026, with revenues of $26.2 million, a remarkable increase of 192% from $9.0 million in Q1 2025. Despite the revenue growth, the company continues to incur net…
Earnings analysis · 10-Q
AUTL earnings analysis
Filed August 11, 2026 · Our reading of the company's report
The latest report
Autolus delivered strong commercial momentum in Q2, with revenue up 118% year over year to $45.689 million, AUCATZYL gross margin at approximately 55.2%, and the net loss narrowing to $39.111 million. Operating cash…
Read full summary
Autolus delivered strong commercial momentum in Q2, with revenue up 118% year over year to $45.689 million, AUCATZYL gross margin at approximately 55.2%, and the net loss narrowing to $39.111 million. Operating cash burn also improved, but the company remains deeply loss-making and incurred $90.386 million of operating cash use in the first half. Liquidity is supported by $201.6 million of cash and marketable securities plus the $75.0 million Perceptive proceeds, although future funding includes expensive, conditional debt and potential dilution. Overall, improved commercialization and efficiency are offset by ongoing capital needs, cost normalization risk and long-dated pipeline milestones.
From revenue to operating profit
Where each $100 of revenue went in this report.
Cost of sales, operating expenses, and what remained. Figures are rounded to whole dollars.
Where revenue came from
The business segments reported by the company.
Shares of the segments disclosed in this filing, largest first.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.15
What stood out
-
AUCATZYL revenue more than doubled
Total revenue increased 118% year over year to $45.689 million from $20.923 million. AUCATZYL product revenue was $45.672 million, driven by higher doses administered, expansion into new treatment centers and U.K. sales.
-
Gross margin expanded to 55%
Gross margin improved to approximately 55.2% from approximately negative 16.8% a year ago, as cost of sales fell to $20.468 million from $24.445 million despite the 118% revenue increase. Management cited higher volumes, improved Nucleus facility utilization and operational efficiencies.
-
Loss and EPS improved
Q2 net loss narrowed 18% to $39.111 million from $47.917 million, while operating loss improved 28% to $43.838 million from $61.217 million. Reported EPS was $(0.15), ahead of the $0.19 consensus loss provided in the earnings row.
-
Revenue growth accompanied by R&D discipline
Six-month revenue rose 140% to $71.907 million from $29.905 million. Six-month R&D expense declined 9% to $49.108 million, primarily from a $12.672 million reduction in direct B-cell malignancy/obe-cel spending.
-
Operating cash burn decreased
Operating cash use declined to $90.386 million in the first half from $148.346 million a year earlier. Property and equipment purchases were $3.6 million, equal to approximately 4.0% of operating cash use.
-
Efficiency program largely completed
The April workforce reduction affected approximately 13% of employees and is expected to reduce operating expenses by approximately $15 million annually beginning in 2027; the majority of the approximately $8 million restructuring charge was recognized in the first half.
What to watch
-
Persistent losses require additional capital
The company remains loss-making, with a $39.111 million Q2 net loss and an accumulated deficit of $1.4975 billion as of June 30, 2026. Management states it expects significant expenses and operating losses for the foreseeable future.
-
Liquidity remains dependent on execution
First-half operating cash outflow was $90.386 million, while cash and cash equivalents were $171.4 million and marketable securities were $30.2 million at June 30, 2026. Management cautions that actual revenues and expenses could vary materially and that additional financing may not be available on acceptable terms.
-
Expensive, conditional financing
The post-quarter Perceptive facility carries interest at one-month SOFR, subject to a 3.50% floor, plus 7.25%, and includes a warrant for up to 3.5 million ADSs at $1.9314 per ADS. Up to $150.0 million of additional capital is contingent on specified revenue milestones, creating financing-cost, dilution and availability risk.
-
Gross margin may face normalization
AUCATZYL cost of sales was $20.468 million, or 45% of revenue, and included $1.2 million of inventory write-downs and $1.6 million of third-party royalties. The filing notes that gross margin benefited from zero-cost inventory, with approximately $0.4 million of additional Q2 cost of sales if previously expensed manufacturing costs were included.
-
Commercial infrastructure weighs on expenses
SG&A increased 36% to $41.161 million from $30.265 million, including $7.4 million of higher salaries and employment-related costs, mainly from termination and severance costs. Management also anticipates higher SG&A as it supports commercialization and public-company requirements.
-
Pipeline timelines remain extended
The 10-Q states that there were no material changes to risk factors from the latest 10-K. Nonetheless, clinical and regulatory execution remains uncertain: pediatric CATULUS data are not expected until the end of 2027, LUMINA data are expected in 2028, and initial AUTO8 data are expected at the end of 2026.
Management's outlook
The 10-Q does not provide numeric revenue or EPS guidance. Management states that $171.4 million of cash, $30.2 million of marketable securities, the $75.0 million received from Perceptive, and expected AUCATZYL proceeds should fund current and planned operating expenses and capital expenditures for at least twelve months from issuance. The filing also states that an additional $25.0 million may be available under the Perceptive facility and up to $150.0 million may become available upon revenue milestones; FY 2026 revenue guidance was disclosed in the prior 8-K rather than this 10-Q.
Earlier filings 4
10-K · March 27, 2026
Autolus’s 10-K emphasizes the transition from clinical-stage to early commercial-stage following regulatory approvals and launches for AUCATZYL (obe-cel). The filing highlights multiple regulatory milestones (FDA BLA…
10-Q · August 12, 2025
Autolus reported its first product revenue following the U.S. commercial launch of AUCATZYL, recognizing $20,923,000 of product revenue in Q2 2025 (and $29,905,000 for the six months). Despite revenue generation and…
10-K · March 20, 2025
Autolus’ 10-K highlights a material commercial inflection: FDA marketing approval for AUCATZYL/obe-cel on November 8, 2024 and a U.S. commercial launch in January 2025. The company positions a modular T‑cell programming…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.